Crombez Eric 4
4 · Ultragenyx Pharmaceutical Inc. · Filed May 5, 2025
Insider Transaction Report
Form 4
Crombez Eric
EVP and Chief Medical Officer
Transactions
- Sale
Common Stock
2025-05-05$39.24/sh−520$20,405→ 71,530 total - Sale
Common Stock
2025-04-21$35.11/sh−242$8,497→ 71,680 total
Footnotes (3)
- [F1]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F2]Includes 370 shares acquired on April 30, 2025 under the Company's Amended and Restated Employee Stock Purchase Plan
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.